5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-Ll Expression 2 50% Ad vance d NSCLC.
| Autor: | Velcheti, Vamsidhar, Rai, Pragya, Yu-Han Kao, Chirovsky, Diana, Nunes, Ana Tablante, Liu, Stephen V. |
|---|---|
| Zdroj: | Clinical Lung Cancer; Sep2024, Vol. 25 Issue 6, p502-508, 7p |
| Databáze: | Complementary Index |
| Externí odkaz: |
|
Full Text from ScienceDirect